Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Introduction Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or
L858R mutation usually respond to epidermal growth factor receptor–tyrosine kinase …

Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …

Background/Aim: To describe real clinical outcomes in patients with non-small cell lung
cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …

Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …